Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Jul;36(7):1499–1503. doi: 10.1128/aac.36.7.1499

Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children.

A Viganò 1, N Principi 1, L Brivio 1, P Tommasi 1, P Stasi 1, A D Villa 1
PMCID: PMC191611  PMID: 1510446

Abstract

The efficacy and safety of netilmicin, 5 mg/kg of body weight once daily or 2 mg/kg thrice daily for 10 days, for the treatment of gram-negative pyelonephritis in children were compared in a prospective, randomized trial. Explicit criteria were used to define the site of infection, treatment outcome, and adverse effects. Netilmicin was given to 74 children once daily and to 70 children three times daily. At 1 week posttreatment, 73 (99%) of 74 children treated with netilmicin once daily and 70 (100%) of 70 children treated with netilmicin three times daily were cured. At 4 weeks posttreatment, no relapse was detected and the rate of reinfection was essentially identical in the two treatment groups. Peak serum netilmicin concentrations were higher in patients given the once-daily regimen, whereas a higher trough level was detected in patients given the three-times-daily regimen. Nephrotoxicity, which was defined as an increase in the serum creatinine level of greater than or equal to 0.3 mg/dl over the baseline, was rare (3%) and reversible and occurred regardless of the treatment regimen. Ototoxicity, which was assessed by pure-tone audiometry (250 to 8,000 Hz) and brain stem-evoked response (6,000 Hz), occurred in 2 of 32 children who were evaluated. In these two children, who were given the once-daily regimen, wave V was not evokable monolaterally below 25 and 40 dB normal hearing level, respectively. Thus, it may be possible to treat childhood pyelonephritis with netilmicin once daily. However, this new approach needs to be confirmed in other studies.

Full text

PDF
1499

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Assael B. M., Parini R., Rusconi F. Ototoxicity of aminoglycoside antibiotics in infants and children. Pediatr Infect Dis. 1982 Sep-Oct;1(5):357–365. doi: 10.1097/00006454-198209000-00017. [DOI] [PubMed] [Google Scholar]
  2. Bauer A. W., Kirby W. M., Sherris J. C., Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966 Apr;45(4):493–496. [PubMed] [Google Scholar]
  3. Bennett W. M., Wood C. A., Houghton D. C., Gilbert D. N. Modification of experimental aminoglycoside nephrotoxicity. Am J Kidney Dis. 1986 Nov;8(5):292–296. doi: 10.1016/s0272-6386(86)80100-7. [DOI] [PubMed] [Google Scholar]
  4. Bergeron M. G. Therapeutic potential of high renal levels of aminoglycosides in pyelonephritis. J Antimicrob Chemother. 1985 Jan;15(1):4–8. doi: 10.1093/jac/15.1.4. [DOI] [PubMed] [Google Scholar]
  5. Brummett R. E., Fox K. E. Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother. 1989 Jun;33(6):797–800. doi: 10.1128/aac.33.6.797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Buring J. E., Evans D. A., Mayrent S. L., Rosner B., Colton T., Hennekens C. H. Randomized trials of aminoglycoside antibiotics: quantitative overview. Rev Infect Dis. 1988 Sep-Oct;10(5):951–957. doi: 10.1093/clinids/10.5.951. [DOI] [PubMed] [Google Scholar]
  7. Daikos G. L., Jackson G. G., Lolans V. T., Livermore D. M. Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis. 1990 Aug;162(2):414–420. doi: 10.1093/infdis/162.2.414. [DOI] [PubMed] [Google Scholar]
  8. Daikos G. L., Lolans V. T., Jackson G. G. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother. 1991 Jan;35(1):117–123. doi: 10.1128/aac.35.1.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Davis H., Hirsh S. K., Turpin L. L., Peacock M. E. Threshold sensitivity and frequency specificity in auditory brainstem response audiometry. Audiology. 1985;24(1):54–70. doi: 10.3109/00206098509070097. [DOI] [PubMed] [Google Scholar]
  10. Edwards C. Q., Smith C. R., Baughman K. L., Rogers J. F., Lietman P. S. Concentrations of gentamicin and amikacin in human kidneys. Antimicrob Agents Chemother. 1976 Jun;9(6):925–927. doi: 10.1128/aac.9.6.925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Eisenberg J. M., Koffer H., Glick H. A., Connell M. L., Loss L. E., Talbot G. H., Shusterman N. H., Strom B. L. What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med. 1987 Dec;107(6):900–909. doi: 10.7326/0003-4819-107-6-900. [DOI] [PubMed] [Google Scholar]
  12. Fan S. T., Lau W. Y., Teoh-Chan C. H., Lau K. F., Mauracher E. H. Once daily administration of netilmicin compared with thrice daily, both in combination with metronidazole, in gangrenous and perforated appendicitis. J Antimicrob Chemother. 1988 Jul;22(1):69–74. doi: 10.1093/jac/22.1.69. [DOI] [PubMed] [Google Scholar]
  13. Gilbert D. N. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother. 1991 Mar;35(3):399–405. doi: 10.1128/aac.35.3.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Houghton D. C., Hartnett M., Campbell-Boswell M., Porter G., Bennett W. A light and electron microscopic analysis of gentamicin nephrotoxicity in rats. Am J Pathol. 1976 Mar;82(3):589–612. [PMC free article] [PubMed] [Google Scholar]
  15. Kahlmeter G., Dahlager J. I. Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother. 1984 Jan;13 (Suppl A):9–22. doi: 10.1093/jac/13.suppl_a.9. [DOI] [PubMed] [Google Scholar]
  16. Mangione A., Schentag J. J. Therapeutic monitoring of aminoglycoside antibiotics: an approach. Ther Drug Monit. 1980;2(2):159–167. doi: 10.1097/00007691-198004000-00010. [DOI] [PubMed] [Google Scholar]
  17. McCracken G. H., Jr Options in antimicrobial management of urinary tract infections in infants and children. Pediatr Infect Dis J. 1989 Aug;8(8):552–555. doi: 10.1097/00006454-198908000-00041. [DOI] [PubMed] [Google Scholar]
  18. McRorie T. I., Bosso J., Randolph L. Aminoglycoside ototoxicity in cystic fibrosis. Evaluation by high-frequency audiometry. Am J Dis Child. 1989 Nov;143(11):1328–1332. doi: 10.1001/archpedi.1989.02150230086028. [DOI] [PubMed] [Google Scholar]
  19. Moore R. D., Lietman P. S., Smith C. R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987 Jan;155(1):93–99. doi: 10.1093/infdis/155.1.93. [DOI] [PubMed] [Google Scholar]
  20. Moore R. D., Smith C. R., Lietman P. S. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med. 1984 Oct;77(4):657–662. doi: 10.1016/0002-9343(84)90358-9. [DOI] [PubMed] [Google Scholar]
  21. Moore R. D., Smith C. R., Lietman P. S. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis. 1984 Mar;149(3):443–448. doi: 10.1093/infdis/149.3.443. [DOI] [PubMed] [Google Scholar]
  22. Olier B., Viotte G., Morin J. P., Fillastre J. P. Influence of dosage regimen on experimental tobramycin nephrotoxicity. A biochemical approach. Chemotherapy. 1983;29(6):385–394. doi: 10.1159/000238225. [DOI] [PubMed] [Google Scholar]
  23. Penn R. G., Preheim L. C., Sanders C. C., Giger D. K. Comparison of moxalactam and gentamicin in the treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 1983 Oct;24(4):494–499. doi: 10.1128/aac.24.4.494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Powell S. H., Thompson W. L., Luthe M. A., Stern R. C., Grossniklaus D. A., Bloxham D. D., Groden D. L., Jacobs M. R., DiScenna A. O., Cash H. A. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis. 1983 May;147(5):918–932. doi: 10.1093/infdis/147.5.918. [DOI] [PubMed] [Google Scholar]
  25. Provoost A. P., Adejuyigbe O., Wolff E. D. Nephrotoxicity of aminoglycosides in young and adult rats. Pediatr Res. 1985 Nov;19(11):1191–1196. doi: 10.1203/00006450-198511000-00016. [DOI] [PubMed] [Google Scholar]
  26. Smith P. B., Tomfohrde K. M., Rhoden D. L., Balows A. API system: a multitube micromethod for identification of Enterobacteriaceae. Appl Microbiol. 1972 Sep;24(3):449–452. doi: 10.1128/am.24.3.449-452.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sturm A. W. Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis. 1989 May;159(5):931–937. doi: 10.1093/infdis/159.5.931. [DOI] [PubMed] [Google Scholar]
  28. Van der Auwera P., Meunier F., Ibrahim S., Kaufman L., Derde M. P., Tulkens P. M. Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection. Antimicrob Agents Chemother. 1991 Apr;35(4):640–647. doi: 10.1128/aac.35.4.640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Vogelman B., Craig W. A. Kinetics of antimicrobial activity. J Pediatr. 1986 May;108(5 Pt 2):835–840. doi: 10.1016/s0022-3476(86)80754-5. [DOI] [PubMed] [Google Scholar]
  30. Vogelman B., Gudmundsson S., Turnidge J., Leggett J., Craig W. A. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis. 1988 Feb;157(2):287–298. doi: 10.1093/infdis/157.2.287. [DOI] [PubMed] [Google Scholar]
  31. Wood C. A., Norton D. R., Kohlhepp S. J., Kohnen P. W., Porter G. A., Houghton D. C., Brummett R. E., Bennett W. M., Gilbert D. N. The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess. J Infect Dis. 1988 Jul;158(1):13–22. doi: 10.1093/infdis/158.1.13. [DOI] [PubMed] [Google Scholar]
  32. ter Braak E. W., de Vries P. J., Bouter K. P., van der Vegt S. G., Dorrestein G. C., Nortier J. W., van Dijk A., Verkooyen R. P., Verbrugh H. A. Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med. 1990 Jul;89(1):58–66. doi: 10.1016/0002-9343(90)90099-y. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES